Laurus Labs Limited — PPTs, 24-01-2025: Investor Presentation

**Investor Presentation Summary for Laurus Labs Limited**

**Financial Highlights:** Revenues for the nine months stood at ₹3,834 Cr, marking a 6% increase year-on-year, supported by strong CDMO performance. EBITDA reached ₹638 Cr with a margin of 16.6%. In Q3, revenues grew 18% to ₹1,415 Cr, while net profit surged 300% to ₹92 Cr.

**Strategic Initiatives and Growth Drivers:** Laurus Labs emphasizes enhancing its CDMO capabilities, including significant investments in a microbial fermentation facility planned for completion by the end of 2026. The company expects continued growth in the CDMO segment, driven by new assets and clinical projects.

**Business Developments:** The completion of a ₹120 Cr equity investment from Eight Roads Ventures aims to strengthen Laurus Bio's capabilities. The strategic collaboration will enable extensive R&D initiatives and bolster the company’s position in sustainable manufacturing technologies.

**Market Position and Competitive Advantage:** Laurus maintains a strong market presence with its diversified offerings in APIs and formulations. The ongoing expansion in R&D and production capabilities positions it favorably to meet increasing global demand.

**Investor Implications:** Positive outlook for revenue growth driven by well-scheduled project deliveries and effective cost management. Continued focus on enhancing operational efficiency and expanding high-margin business segments could present attractive growth opportunities for investors.